KR870000427A - 하이브리드 인터페론의 제조방법 - Google Patents

하이브리드 인터페론의 제조방법 Download PDF

Info

Publication number
KR870000427A
KR870000427A KR1019860004580A KR860004580A KR870000427A KR 870000427 A KR870000427 A KR 870000427A KR 1019860004580 A KR1019860004580 A KR 1019860004580A KR 860004580 A KR860004580 A KR 860004580A KR 870000427 A KR870000427 A KR 870000427A
Authority
KR
South Korea
Prior art keywords
hybrid
interferon
lyifn
hybrid interferon
polypeptide
Prior art date
Application number
KR1019860004580A
Other languages
English (en)
Other versions
KR920002267B1 (ko
Inventor
메이어 프랑코이스
힌넨 알베르트
마이스터 안드레아스
케르하르트 그뤼터 마르쿠스
알칸 세피크
Original Assignee
시바-가이기 코포레이션
아놀드 자일러, 에른스트 알테르
시바-가이기 에이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858514725A external-priority patent/GB8514725D0/en
Priority claimed from GB858514723A external-priority patent/GB8514723D0/en
Priority claimed from GB858514726A external-priority patent/GB8514726D0/en
Priority claimed from GB858514724A external-priority patent/GB8514724D0/en
Priority claimed from GB858514722A external-priority patent/GB8514722D0/en
Application filed by 시바-가이기 코포레이션, 아놀드 자일러, 에른스트 알테르, 시바-가이기 에이지 filed Critical 시바-가이기 코포레이션
Publication of KR870000427A publication Critical patent/KR870000427A/ko
Application granted granted Critical
Publication of KR920002267B1 publication Critical patent/KR920002267B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

내용 없음

Description

하이브리드 인터페론의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제2도는 LyIFN-α-2 및 LyIFN-α-3의 코드화 부위의 뉴클레오타이드 서열이다.
제3도는 플라스미드 CG-pBR(AP)/LyIFN-α-2 및 CG-pBR(AP)/LyIFN-α-3의 Hind III-Pst I 소단편의 제한 지도이다.

Claims (9)

  1. 하이브리드 인터페론 폴리펩티드를 코드화하는 DNA서열을 함유하는 하이브리드 벡터로 형질전환시킨 숙주세포를 배양하여, 하이브리드 인터페론을 분리시킴을 특징으로 하여, 아미노산 동일성 및 수에 있어서 인체 임파아구 인터페론 LyIFN-α-2 및 LyIFN-α-3의 아서열에 상응하는 2내지 4개의 아서열로 이루어진 아미노산 서열을 갖는 하이브리드 인터페론 폴리펩티드 [여기에서, 상기 하이브리드 인터페론 폴리펩티드는, LyIFN-α-2의 아미노산 1내지 150 및 LyIFN-α-3의 아미노산 151내지 166으로 이루어진 아미노산 서열을 갖는 폴리펩티드 ; LyIFN-α-2의 아미노산 1내지 92, LyIFN-α-3의 아미노산 93내지 150 및 LyIFN-α-2의 아미노산 151내지 166으로 이루어진 아미노산 서열을 갖는 폴리페티드 ; 및 LyIFN-α-2의 아미노산 1내지 60, LyIFN-α-3의 아미노산 61내지 92, LyIFN-α-2 또는 LyIFN-α-3의 아미노산 93내지 150 및 LyIFN-α-2 또는 LyIFN-α-3의 아미노산 151내지 166으로 이루어진 아미노산 서열을 갖는 폴리펩티드로 이루어진 그룹중에서 선택된다]를 제조하는 방법.
  2. 제1항에 있어서, 하이브리드 인터페론 폴리펩티드를, 하기 일반식(I)을 갖는 하이브리드 인터페론 폴리펩티드 "B1B2B3D4", 하기 일반식(II)을 갖는 하이브리드 인터페론 폴리펩티드 "B1B2D3B4", 하기 일반식(III)을 갖는 하이브리드 인터페론 폴리펩티드 "B1D2B3D4", 하기 일반식(IV)을 갖는 하이브리드 인터페론 폴리펩티드 "B1D2D3B4",하기 일반식(V)을 갖는 하이브리드 인터페론 폴리펩티드 "B1D2D3D4" 및 하기 일반식(VI)을 갖는 하이브리드 인터페론 폴리펩티드 "B1D2B3B4"로 이루어진 그룹중에서 선택함을 특징으로 하는 방법.
  3. 제1항에 있어서, 하이브리드 벡터가 하이브리드 인터페론 "B1B2B3D4"를 코드화하는 DNA 서열을 함유함을 특징으로 하여 하이브리드 인터페론 "B1B2B3D4"를 제조하는 방법.
  4. 제1항에 있어서, 하이브리드 벡터가 하이브리드 인터페론 "B1B2D3B4"를 코드화하는 DNA 서열을 함유함을 특징으로 하여 하이브리드 인터페론 "B1B2D3B4"를 제조하는 방법.
  5. 제1항에 있어서, 하이브리드 벡터가 하이브리드 인터페론 "B1D2B3B4"를 코드화하는 DNA 서열을함유함을 특징으로 하여 하이브리드 인터페론 "B1D2B3D4"를 제조하는 방법.
  6. 제1항에 있어서, 하이브리드 벡터가 하이브리드 인터페론 "B1D2D3B4"를 코드화하는 DNA 서열을 함유함을 특징으로 하여 하이브리드 인터페론 "B1D2D3B4"를 제조하는 방법.
  7. 제1항에 있어서, 하이브리드 벡터가 하이브리드 인터페론 "B1D2D3D4"를 코드화하는 DNA 서열을 함유함을 특징으로 하여 하이브리드 인터페론 "B1D2D3D4"를 제조하는 방법.
  8. 제1항에 있어서, 하이브리드 벡터가 하이브리드 인터페론 "B1D2B3B4"를 코드화하는 DNA 서열을 함유함을 특징으로 하여 하이브리드 인터페론 "B1D2B3B4"를 제조하는 방법.
  9. 제1항에 있어서,
    a) 인터페론 LyIFN-α-2 및 LyIFN-α-3의 각 아미노산 60,92 및 150에 상응하는 부위에서 시험관내(in vitro) 재조합법에 의해 또는 화학적 DNA 합성법에 의해, 상기 하이브리드 인터페론을 코드화하는 구조성 유전자(Structural gene)로 이루어진 DNA를 제조한다음, 수득된 DNA를 적절한 발현벡터(expression vector)내로 혼입시키고,
    b) 하이브리드 IFN구조성 유전자를 함유하는 수득된 하이브리드 벡터를 수령 숙주(recipient host)내로 전이시키고,
    c) 형질전환된 숙주를, 형질전환된 숙주만이 생존할 수 있는 그러한 조건하에서 배양시킴에 의해, 형질전환되지 않은 숙주로부터 선별하고,
    d) 형질전환된 숙주를, 하이브리드 IFN구조성 유전자의 발현을 허용하는 조건하에 배양한 다음
    e) 발현된 하이브리드 IFN을 분리시키는 단계로 이루어진 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860004580A 1985-06-11 1986-06-10 하이브리드 인터페론의 제조방법 KR920002267B1 (ko)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GB8514724 1985-06-11
GB858514725A GB8514725D0 (en) 1985-06-11 1985-06-11 Hybrid polypeptide
GB858514723A GB8514723D0 (en) 1985-06-11 1985-06-11 Hybrid alpha-interferon
GB858514726A GB8514726D0 (en) 1985-06-11 1985-06-11 Hybrid polypeptides
GB8514725 1985-06-11
GB8514726 1985-06-11
GB8514723 1985-06-11
GB858514724A GB8514724D0 (en) 1985-06-11 1985-06-11 Hybrid alpha-interferon
GB8514722 1985-06-11
GB858514722A GB8514722D0 (en) 1985-06-11 1985-06-11 Hybrid interferon

Publications (2)

Publication Number Publication Date
KR870000427A true KR870000427A (ko) 1987-02-18
KR920002267B1 KR920002267B1 (ko) 1992-03-20

Family

ID=27516593

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860004580A KR920002267B1 (ko) 1985-06-11 1986-06-10 하이브리드 인터페론의 제조방법

Country Status (20)

Country Link
US (2) US4885166A (ko)
EP (1) EP0205404B1 (ko)
JP (2) JPH0655759B2 (ko)
KR (1) KR920002267B1 (ko)
AT (1) ATE78262T1 (ko)
AU (1) AU598196B2 (ko)
CA (1) CA1285507C (ko)
CY (1) CY1842A (ko)
DE (1) DE3685996T2 (ko)
DK (1) DK168794B1 (ko)
FI (1) FI90983C (ko)
GR (1) GR861497B (ko)
HK (1) HK99895A (ko)
HU (1) HU203255B (ko)
IE (1) IE57865B1 (ko)
IL (1) IL79085A (ko)
NO (1) NO175602C (ko)
NZ (1) NZ216485A (ko)
PT (1) PT82736B (ko)
SG (1) SG25195G (ko)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359035A (en) * 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
DE3607835A1 (de) * 1986-03-10 1987-09-24 Boehringer Ingelheim Int Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
GB8803365D0 (en) * 1988-02-13 1988-03-16 Ciba Geigy Ag Antiviral combination
EP0331635A3 (en) * 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Preparations for treating bladder cancer
US5273889A (en) * 1990-08-22 1993-12-28 University Of Saskatchewan Gamma-iterferon-leukotoxin gene fusions and uses thereof
US5594107A (en) * 1990-08-22 1997-01-14 University Of Saskatchewan Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
ES2118756T5 (es) * 1990-08-29 2004-01-16 Genetics Institute, Llc Estimuladores de hematopoyesis de multiples dominios.
US5372808A (en) † 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
ATE157703T1 (de) * 1991-12-16 1997-09-15 Ciba Geigy Ag Endoplasmatisches retikulum-ständige rekombinante dibasische endoprotease und deren verwendungen
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
CA2102294A1 (en) * 1992-03-10 1993-09-11 Jose L. Millan Recombinant calf intestinal alkaline phosphatase
TW218846B (ko) * 1992-04-07 1994-01-11 Ciba Geigy
JPH078215A (ja) * 1993-04-30 1995-01-13 Kawasaki Steel Corp ドコサヘキサエン酸含有海洋性微細藻類食品素材およびその製造方法
TW249202B (ko) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
ES2167537T3 (es) 1995-02-09 2002-05-16 Novartis Ag Procedimiento para la produccion de proteinas.
TW442492B (en) * 1995-07-26 2001-06-23 Novartis Ag Process for the enrichment of interferon
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
LT2599503T (lt) 1998-10-16 2017-06-26 Biogen Ma Inc. Interferono beta-1a polimero konjugatai ir jų panaudojimas
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US20020197235A1 (en) 2000-11-03 2002-12-26 Moran Stanford Mark Method for short-term and long-term drug dosimetry
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
FR2821625B1 (fr) * 2001-03-01 2003-05-16 Genodyssee Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823220B1 (fr) * 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
DE60237721D1 (de) * 2001-11-09 2010-10-28 Intarcia Therapeutics Inc Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
JP2006506097A (ja) * 2002-11-18 2006-02-23 マキシジェン， インコーポレイテッド インターフェロン−αのポリペプチドおよび結合体
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1753779A2 (en) * 2004-05-19 2007-02-21 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
WO2006004959A2 (en) * 2004-06-30 2006-01-12 Egen Corporation Pegylated interferon alpha-1b
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
MX2007014524A (es) 2005-05-18 2008-02-07 Maxygen Inc Polipeptidos desarrollados de interferon-alfa.
ES2351527T3 (es) 2006-05-30 2011-02-07 Intarcia Therapeutics, Inc Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
US8119368B2 (en) 2006-07-14 2012-02-21 Dsm Ip Assets B.V. Process for the culturing of cells
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
BRPI0719912A2 (pt) 2006-12-06 2014-03-04 Medimmune Llc Método para tratar lupus eritematoso sistêmico, e, método para reduzir elevações passageiras de índice de atividade da doença lupus eritematoso sistêmico
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
EP2076533B1 (en) * 2007-05-02 2014-10-08 Ambrx, Inc. Modified interferon beta polypeptides and their uses
EP2068924A4 (en) 2007-05-03 2011-07-20 Medimmune Llc INTERFERON ALPHA INDUCED PHARMACODYNAMIC MARKERS
US7625555B2 (en) * 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
BRPI0819195A2 (pt) 2007-11-05 2017-05-23 Medimmune Llc métodos para tratar escleroderma em um paciente em necessidade de tal tratamento e para aliviar um ou mais dos sintomas associados com escleroderma em um paciente em necessidade de tal tratamento.
EP2848702A1 (en) 2008-02-08 2015-03-18 MedImmune, LLC Disease markers and uses thereof
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
CA2772921A1 (en) 2009-09-03 2011-03-10 Medimmune, Llc Type 1 interferon diagnostic
EP3323423B1 (en) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
PL2686002T3 (pl) 2011-03-15 2018-10-31 Biogen Ma Inc. Sposób łagodzenia symptomów grypopodobnych związanych z domięśniowym podawaniem interferonu przy wykorzystaniu schematu zwiększania dawki z szybkim miareczkowaniem
US8729236B2 (en) * 2011-05-23 2014-05-20 Hal S. Padgett Selection and characterization of novel plant-derived recombinant human interferons with broad spectrum activity
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MA44390A (fr) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc Systèmes de mise en place et de retrait d'implant
SG11201810102SA (en) 2016-05-16 2018-12-28 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
EA202192176A1 (ru) 2019-02-15 2022-01-13 Астразенека Аб Нарушения, опосредованные интерфероном i типа
KR102594862B1 (ko) * 2023-06-14 2023-10-27 (주) 신성하이스킬 화재방지 파쇄 시스템
KR102570958B1 (ko) * 2023-06-14 2023-08-25 (주) 신성하이스킬 화재방지 4축 파쇄장치

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341567C (en) * 1980-01-08 2008-02-19 Charles Weissmann Dna sequences, recombinant dna molecules and processes for producing human interferon - like polypeptides
US4456748A (en) * 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
ES8302778A1 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
GB2108510B (en) * 1981-10-03 1984-12-12 Ciba Geigy Ag Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof
IT1167610B (it) * 1982-01-19 1987-05-13 Cetus Corp Interfreron ibrido multiclasse, composizione farmaceutica che lo contiene e procedimento di produzione
GB8315980D0 (en) * 1983-06-10 1983-07-13 Biogen Nv Producing hybrid dna sequences
GB8317880D0 (en) * 1983-07-01 1983-08-03 Searle & Co Structure and synthesis of interferons
EP0146903A3 (en) * 1983-12-19 1987-07-22 Schering Corporation Production of a vector encoding a novel hybrid interferon species
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
EP0173935A1 (en) * 1984-08-31 1986-03-12 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons
US4716217A (en) * 1984-08-31 1987-12-29 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons

Also Published As

Publication number Publication date
NZ216485A (en) 1991-06-25
EP0205404A3 (en) 1987-10-21
SG25195G (en) 1995-08-18
PT82736A (en) 1986-07-01
KR920002267B1 (ko) 1992-03-20
HU203255B (en) 1991-06-28
HUT41846A (en) 1987-05-28
CY1842A (en) 1996-03-08
JPH0655759B2 (ja) 1994-07-27
JPH0736757B2 (ja) 1995-04-26
FI90983C (fi) 1994-04-25
FI862461A (fi) 1986-12-12
DK272986A (da) 1986-12-12
AU5849986A (en) 1986-12-18
DE3685996T2 (de) 1993-01-14
NO175602C (no) 1994-11-02
IE57865B1 (en) 1993-05-05
EP0205404B1 (en) 1992-07-15
NO862313D0 (no) 1986-06-10
AU598196B2 (en) 1990-06-21
DE3685996D1 (de) 1992-08-20
US4885166A (en) 1989-12-05
US5071761A (en) 1991-12-10
NO862313L (no) 1986-12-12
IL79085A (en) 1992-03-29
JPS626000A (ja) 1987-01-12
IE861542L (en) 1986-12-11
NO175602B (no) 1994-07-25
IL79085A0 (en) 1986-09-30
GR861497B (en) 1986-10-10
CA1285507C (en) 1991-07-02
PT82736B (pt) 1988-12-15
JPH05308973A (ja) 1993-11-22
ATE78262T1 (de) 1992-08-15
FI862461A0 (fi) 1986-06-09
DK272986D0 (da) 1986-06-10
HK99895A (en) 1995-06-30
EP0205404A2 (en) 1986-12-17
FI90983B (fi) 1994-01-14
DK168794B1 (da) 1994-06-13

Similar Documents

Publication Publication Date Title
KR870000427A (ko) 하이브리드 인터페론의 제조방법
US5464939A (en) Highly purified protein, production and use thereof
RU2004126135A (ru) Новый цитокин zalpha11-лиганд
NL930127I1 (nl) Vorming van een meervoudig werkzame granulocytkolonie-stimulerende factor
KR880011342A (ko) 비a 비b형 간염 특이 항원을 코딩하는 dna 단편, 이 dna 단편을 함유하는 발현 벡터, 형질전환체 및 이 항원의 제조방법
ES8605534A1 (es) Procedimiento para producir un vehiculo de expresion de adn-replicable.
ATE140009T1 (de) Interleukin-4 protein mit bcgf- und tcgf- aktivität gegenüber menschlichen zellen (menschliches interleukin-4)
KR970701199A (ko) 성장 정지 호메오박스 유전자(Growth Arrest Homeobox Gene)
MX26714A (es) Procedimiento para la preparacion de albumina de SUERO HUMANO VECTOR Y PLASMIDO USADOS ASI COMO LEVADURA METILOTROFICA TRANSFORMADA OBTENIDA
KR900014428A (ko) 신규폴리펩타이드 및 그 제조방법
DE3751368D1 (de) gentechnische Herstellung von Faktor XIIIa.
JPS6485098A (en) Glycoprotein and production thereof
NO862690D0 (no) Monoklonale antistoffer og antigener for humane ikke-liten-celle lungekarcinomer (nsclc).
KR900702009A (ko) 인체 a형 모노아민 옥시다제를 코오딩 하는 dna
KR910001058A (ko) 고양이 인터페론 및 이의 제조방법
KR880005264A (ko) 사카로미세스 세레비시아에에서 재조합 인간 psti제법
KR890013177A (ko) 신규폴리펩티드 및 그것을 코우드하는 dna
ES2052562T3 (es) Peptido antineoplasico inducido por la interleucina-2.
KR880003008A (ko) 우역 바이러스의 항원 단백질을 코드화 하는 dna
KR850006704A (ko) 인체 감마 인터페론의 제조방법
KR880007720A (ko) 유전자 재조합 기술에 의한 사람 알파 인터페론의 제조방법
KR950018458A (ko) 씨(c)형 간염 바이러스의 외피2 단백질의 제조를 위한 재조합 백시니아 바이러스 및 포유 동물 세포에서의 발현.

Legal Events

Date Code Title Description
A201 Request for examination
E601 Decision to refuse application
E902 Notification of reason for refusal
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20050127

Year of fee payment: 14

LAPS Lapse due to unpaid annual fee